

ドキシル注20mgに関する資料

本資料に記載された情報に係る権利及び内容の責任はヤンセンファーマ株式会社に帰属するものであり、当該情報を適正使用以外の営利目的に利用することはできません。

ヤンセン ファーマ株式会社

CL55-LTI-30-SM-94-55

CONFIDENTIAL

OVERALL NDA SUMMARY:

DOXIL® (STEALTH® LIPOSOMAL DOXORUBICIN HYDROCHLORIDE)

August 29, 1994

**Liposome Technology, Inc.
960 Hamilton Court
Menlo Park, California 94025**

TABLE OF CONTENTS

	<u>Page</u>
I. ANNOTATED PACKAGE INSERT	1
II. PHARMACOLOGIC CLASS, SCIENTIFIC RATIONALE AND INTENDED USE.....	31
A. Pharmacologic Class of Drug Substance	31
B. Scientific Rationale.....	31
1. Conventional Liposomes	32
2. Long-circulating "Stealth" Liposomes	33
C. Intended Use of DOXIL.....	35
D. Summary	35
III. MARKETING HISTORY	37
IV. SUMMARY OF THE CHEMISTRY, MANUFACTURING AND CONTROLS DATA.....	39
A. Drug Substance	39
B. Drug Product.....	40
1. Specifications and Analytical Methods for Drug Product Ingredients	41
2. Manufacturer Information.....	42
3. Method of Manufacture and Packaging	42
4. Regulatory Specifications and Testing Procedures for Acceptance of the Drug Product.....	43
5. Container-Closure System	44
6. Microbiology.....	44
7. Drug Product Stability	44
8. Environmental Assessment.....	44
C. Investigational Formulae	45
V. SUMMARY OF THE NONCLINICAL PHARMACOLOGY AND TOXICOLOGY SECTION	47
A. Introduction.....	47
B. Nonclinical Efficacy Studies.....	48
1. Mechanism of Doxorubicin Action	48
2. Effects of DOXIL on Transplantable Tumors in Mice	48
3. Summary	52

CONFIDENTIAL

DOXIL[®]
Liposome Technology, Inc.

Overall NDA Summary
August 29, 1994

C.	General Pharmacology	60
1.	Neurologic Effects	60
2.	Cardiovascular Effects	60
D.	Nonclinical Absorption, Distribution, Metabolism and Excretion (ADME) Summary	64
1.	Introduction	64
2.	Plasma Pharmacokinetics	65
3.	Tissue Distribution	74
4.	Metabolism	79
5.	Excretion	79
6.	Summary	80
E.	Nonclinical Toxicology	95
1.	Introduction	95
2.	Acute Toxicity Studies	96
3.	Repeat Dose Studies	97
4.	Special Toxicity Studies	101
5.	Reproductive Studies	102
6.	Mutagenicity and Genotoxicity Studies	103
7.	Summary	104
8.	Final Summary	123
VI.	HUMAN PHARMACOKINETIC SUMMARY	127
A.	Introduction	127
B.	Pharmacokinetics of DOXIL (Study 30-14)	127
C.	Amount of Non-liposomal Doxorubicin in Plasma	129
D.	Comparison of DOXIL Pharmacokinetic Parameters (Study 30-14) to Literature Values for Adriamycin Pharmacokinetic Parameters	130
E.	Comparison of DOXIL and DOXIL 1 Pharmacokinetic Parameters (Studies 30-05 and 30-14)	131
F.	Doxorubicin Levels in KS Lesions (Studies 30-05 and 30-14)	133
VII.	MICROBIOLOGY SUMMARY	139
VIII.	CLINICAL DATA SUMMARY	140
A.	Introduction	140
B.	Clinical Pharmacology	142
1.	Clinical Pharmacology/Pharmacokinetics of DOXIL	143
2.	Clinical Pharmacology/Pharmacokinetics of DOXIL 1	145
3.	Overall Summary of the Clinical Pharmacokinetics of DOXIL	147
C.	Overview of Clinical Studies	151

CONFIDENTIAL

DOXIL®
Liposome Technology, Inc.

Overall NDA Summary
August 29, 1994

D.	Efficacy Studies Supporting Indication	153
1.	Methodology: Measuring KS Response	154
2.	Efficacy Results	157
3.	Discussion of Results from Efficacy Trials	165
4.	Efficacy Conclusions	166
E.	Safety Summary - General Safety Conclusions.....	169
1.	Primary Database	169
2.	Secondary Safety Database.....	186
3.	Clinical Laboratory Data (Chemistry, Hematology, Urinalysis, etc.)	187
4.	Clinical Literature Review.....	187
IX.	DISCUSSION OF BENEFIT/RISK RELATIONSHIP AND PROPOSED POSTMARKETING STUDIES.....	191
A.	Patient Population	191
B.	Clinical Indication and Patient Profile.....	191
C.	Clinical Benefit	192
D.	Risks	194
E.	Conclusions.....	197
X.	REFERENCES AND NOTES	199

TABLE LEGEND

TABLE 1:	Countries where DOXIL Injection is Available Under Named Patient Sale	37
TABLE 2:	Number of Patients Treated by Country Under Named Patient Use Program	38
TABLE 3:	DOX-SL Injection Composition	40
TABLE 4:	Excipient Quality Standards	41
TABLE 5:	DOX-SL Injection Regulatory Specifications	43
TABLE 6:	Investigational Formulae	45
TABLE 7:	Summary of Clinical Lot Disposition	46
TABLE 8:	Summary of DOXIL Formulations used in Nonclinical Studies	49
TABLE 9:	Summary Table of Pharmacology Studies of DOXIL	54
TABLE 10:	Summary Table of General Pharmacology Studies	62
TABLE 11:	Pharmacokinetics of DOXIL in Rats	66
TABLE 12:	Mean Pharmacokinetic Parameters of DOXIL and Adriamycin in Rats	68
TABLE 13:	Mean Pharmacokinetic Parameters of DOXIL 3 and DOXIL 2 in Rats	69
TABLE 14:	Plasma Concentration of Doxorubicin after Treatment with DOXIL or Adriamycin.....	70
TABLE 15:	Tissue AUCs in C26 Tumor-Bearing Mice Treated with DOXIL or Adriamycin.....	74
TABLE 16:	Peak Doxorubicin Concentrations in Tissues of Rats that Received a Single Dose of DOXIL or Adriamycin	77

CONFIDENTIAL

DOXIL®
Liposome Technology, Inc.

Overall NDA Summary
August 29, 1994

TABLE 17:	Ratio of Tissue Concentrations of Doxorubicin After One or Thirteen Doses of 1 mg/kg DOXIL or Adriamycin.....	78
TABLE 18:	Summary Table of Nonclinical Plasma Pharmacokinetic Studies with DOXIL	82
TABLE 19:	Summary Table of Nonclinical Tissue Distribution Studies with DOXIL	90
TABLE 20:	Summary Table of Acute Toxicology Studies of DOXIL	106
TABLE 21:	Summary Table of Repeat Dose Toxicology Studies of DOXIL	108
TABLE 22:	Summary Table of Special Toxicology Studies of DOXIL	111
TABLE 23:	Summary Table of Reproductive Toxicology Studies of DOXIL	113
TABLE 24:	Summary Table of Mutagenicity Studies of DOXIL.....	114
TABLE 25:	Pharmacokinetic Studies of DOXIL Formulations.....	127
TABLE 26:	DOXIL Pharmacokinetic Parameter Estimates.....	128
TABLE 27:	Summary of Median (range) DOXIL and DOXIL 1 Pharmacokinetic Parameters.....	132
TABLE 28:	Range of Doxorubicin Concentrations in KS Lesions from DOXIL- and DOXIL 1-treated Patients.....	133
TABLE 29:	Concentration of Doxorubicin in KS Lesions and Normal Skin After DOXIL Administration.....	134
TABLE 30:	Predicted Accumulation of Doxorubicin in KS Lesions and Skin Samples	135
TABLE 31:	Accumulation Ratio of Doxorubicin in KS Lesions and Skin Samples.....	135
TABLE 32:	Accumulation Ratio of Doxorubicin in KS Lesions and Skin Samples.....	136

CONFIDENTIAL

DOXIL®
Liposome Technology, Inc.

Overall NDA Summary
August 29, 1994

TABLE 33:	Comparison of Doxorubicin Concentration in KS Lesion After DOXIL 1 or Adriamycin Administration.....	137
TABLE 34:	Overview of DOXIL Clinical Studies Contained in NDA	141
TABLE 35:	Summary of DOXIL Formulations used in Clinical Trials	142
TABLE 36:	Overview of Open-label, Randomized, Crossover Clinical Pharmacology Studies.....	143
TABLE 37:	Summary of Median (Range) DOXIL and DOXIL 1 Pharmacokinetic Parameters.....	149
TABLE 38:	Overview of Clinical Studies Supporting the Indication	153
TABLE 39:	Demographic Summary (KS Patients Only).....	158
TABLE 40:	Best Response and Duration of Partial or Complete Responses.....	160
TABLE 41:	Clinical Benefits by Best Response	163
TABLE 42:	Quality of Life Comparison from Study 30-03.....	164
TABLE 43:	Enumeration of Patients Exposed to DOXIL in the Primary Safety Database.....	169
TABLE 44:	Summary of Exposure to DOXIL: Primary Safety Database	171
TABLE 45:	Summary of Adverse Events	173
TABLE 46:	Summary of Cardiovascular System Adverse Events by COSTART Preferred Term (KS Patients Only).....	182
TABLE 47:	Opportunistic Infections.....	185
TABLE 48:	Enumeration of Patients Exposed (or to be exposed) to DOXIL in Clinical Trials: Secondary Safety Database (Date: May 31, 1994) ...	186
TABLE 49:	Clinical Benefits by Best Response	193

FIGURES

FIGURE 1:	Diagram of PEG-stabilized "Stealth" Liposome	33
FIGURE 2:	Plasma Concentration of doxorubicin in rats treated with DOXIL. ...	65
FIGURE 3:	Plasma concentration of doxorubicin in rats received a single intravenous injection of 4.0 mg/kg DOXIL or DOXIL 1	70
FIGURE 4:	Plasma concentration of doxorubicin in rabbits treated with single intravenous injection of 1.5 mg/kg DOXIL or Adriamycin	71
FIGURE 5:	Plasma concentration of doxorubicin in dogs that received a single intravenous injection of 1.5 mg/kg DOXIL or DOXIL 1	73
FIGURE 6:	Concentration of doxorubicin in human prostatic carcinoma xenografts in nude mice treated with 0.9 mg/kg DOXIL or 0.9 mg/kg Adriamycin	76
FIGURE 7:	Plasma Clearance of Adriamycin and DOXIL 1	129